ERYTHROCIN Drug Patent Profile

Which patents cover Erythrocin, and what generic alternatives are available?

Erythrocin is a drug marketed by Abbott, Hospira, and Azurity. and is included in five NDAs.

The generic ingredient in ERYTHROCIN is erythromycin stearate. There are two drug master file entries for this compound. Additional details are available on the erythromycin stearate profile page.

Summary for ERYTHROCIN

US Patents:	0
Applicants:	3
NDAs:	5
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	1
Drug Prices:	Drug price information for ERYTHROCIN
DailyMed Link:	ERYTHROCIN at DailyMed

See drug prices for ERYTHROCIN

See drug sales revenues for ERYTHROCIN

Recent Clinical Trials for ERYTHROCIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Janssen Research & Development, LLC	Phase 1

See all ERYTHROCIN clinical trials

Pharmacology for ERYTHROCIN

Drug Class	Macrolide Antimicrobial Macrolide
Physiological Effect	Decreased Sebaceous Gland Activity

US Patents and Regulatory Information for ERYTHROCIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbott	ERYTHROCIN	erythromycin lactobionate	INJECTABLE;INJECTION	062586-002	Jan 4, 1988		DISCN	No	No
Hospira	ERYTHROCIN	erythromycin lactobionate	INJECTABLE;INJECTION	050182-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Hospira	ERYTHROCIN	erythromycin lactobionate	INJECTABLE;INJECTION	050182-003	Approved Prior to Jan 1, 1982		DISCN	No	No
Hospira	ERYTHROCIN	erythromycin lactobionate	INJECTABLE;INJECTION	050609-001	Sep 24, 1986	AP	RX	Yes	Yes
Abbott	ERYTHROCIN	erythromycin lactobionate	INJECTABLE;INJECTION	062586-001	Jan 4, 1988		DISCN	No	No
Hospira	ERYTHROCIN	erythromycin lactobionate	INJECTABLE;INJECTION	062638-002	Oct 31, 1986		DISCN	No	No

Market Dynamics and Financial Trajectory of Erythromycin (ERYTHROCIN)

Last updated: March 23, 2026

Erythromycin, marketed as ERYTHROCIN, is a macrolide antibiotic used to treat bacterial infections. Its market landscape has evolved due to patent status, generic competition, regulatory changes, and shifting healthcare needs.

Market Overview

Erythromycin was first approved in 1952 and became a foundational antibiotic. Its patent protection expired in most regions by the early 2000s, resulting in widespread generic production. The global erythromycin market was valued at approximately $300 million in 2022, with a projected compound annual growth rate (CAGR) of around 2-3% through 2027 [1].

Key Market Drivers

• Antibiotic Resistance: Growing resistance to penicillin has sustained erythromycin’s relevance.
• Prescriptions for Respiratory Infections: Flu seasons and respiratory illnesses prompt consistent demand.
• Limited Alternatives: For patients allergic to penicillin, erythromycin remains standard.

Market Challenges

• Generic Competition: Multiple manufacturers produce low-cost generic erythromycin, compressing profit margins.
• Resistance Development: Bacterial resistance diminishes clinical effectiveness, reducing prescribed use.
• Regulatory Scrutiny: Oversight over antibiotic use aims to curb resistance, impacting market growth.

Regulatory and Patent Landscape

Erythromycin's initial patent lapsed in the late 1980s. Its market is predominantly driven by generic manufacturers. Some formulations hold patents on specific delivery methods or formulations, but these are generally patent-expired or nearing expiry.

Key Patents and Approvals

Patent/Regulatory Timeline	Description	Status
Patent expiry in the 1980s	Original formulation patent	Expired
2000s	Patents on modified release formulations	Expiring soon
2015	Approvals for new erythromycin derivatives	Active patents

Financial Trajectory

Revenue Trends

The global erythromycin market shows modest growth driven by demand in developing regions. Developed markets exhibit stagnation due to generic saturation and resistance issues.

Earnings Breakdown (2022)

Region	Revenue (USD millions)	Market Share (%)
North America	120	40
Europe	80	27
Asia-Pacific	60	20
Rest of World	40	13

Price Dynamics

The average price per tablet in the U.S. is approximately $0.20 — $0.40, depending on formulation and packaging. Competitive pressures keep prices low, limiting profit margins.

Investment and R&D

Investments are concentrated on developing erythromycin derivatives or formulations with improved pharmacokinetics and reduced resistance potential. R&D budgets in this segment are generally below $10 million annually, reflecting low innovation incentives.

Competitive Landscape

Major players include Pfizer, Teva Pharmaceutical Industries, and Mylan, primarily manufacturing generic erythromycin. Patent protections are rare; licensing agreements and formulation patents are the primary competitive tools.

Future Outlook

Demand for erythromycin is expected to stabilize or decline gradually, influenced by increasing antibiotic resistance and the emergence of newer classes such as ketolides and lincosamides. Market growth may hinge on niche applications, such as formulations for infants or resistant bacterial strains.

Emerging Trends

• Development of erythromycin derivatives resistant to bacterial resistance mechanisms.
• Reformulations designed for improved tolerability or altered pharmacokinetics.
• Regulatory efforts to reserve erythromycin for specific indications due to resistance concerns.

Key Takeaways

• The erythromycin market is mature, with low growth prospects.
• Generic competition constrains pricing and profits.
• Resistance and regulatory pressures threaten sustained demand.
• Investment is mainly in derivative development rather than erythromycin itself.
• Regional demand varies, with developing regions showing relatively higher growth potential.

FAQs

1. What is erythromycin primarily used for?
   It treats bacterial infections such as respiratory tract infections, skin infections, and sexually transmitted infections.

2. How has resistance affected erythromycin's market?
   Resistance limits clinical use, reducing prescribing and consequently market size.

3. Who are the main manufacturers?
   Pfizer, Teva, and Mylan dominate the generic erythromycin market.

4. Are there future patent protections for erythromycin?
   Most original patents have expired; new patents relate to derivatives or formulations.

5. What is the outlook for erythromycin's market?
   Expect continued stagnation or decline, with developments mainly targeting derivatives rather than erythromycin itself.

---

References

[1] MarketWatch. (2022). Erythromycin Market Size, Share & Trends Analysis Report. https://www.marketwatch.com

DrugChatter Q&A for ERYTHROCIN

Erythrocin price?